Campbell Rogers Sells 64,533 Shares of Heartflow (NASDAQ:HTFL) Stock

Heartflow, Inc. (NASDAQ:HTFL) insider Campbell Rogers sold 64,533 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $24.64, for a total value of $1,590,093.12. Following the sale, the insider owned 81,002 shares of the company’s stock, valued at $1,995,889.28. This represents a 44.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Campbell Rogers also recently made the following trade(s):

• On Thursday, March 19th, Campbell Rogers sold 64,533 shares of Heartflow stock. The stock was sold at an average price of $25.69, for a total value of $1,657,852.77.
• On Thursday, February 12th, Campbell Rogers sold 65,153 shares of Heartflow stock. The shares were sold at an average price of $24.49, for a total value of $1,595,596.97.

Heartflow Price Performance

Shares of NASDAQ HTFL opened at $24.83 on Friday. Heartflow, Inc. has a fifty-two week low of $20.13 and a fifty-two week high of $41.22. The business has a 50 day moving average price of $25.12 and a two-hundred day moving average price of $29.89. The firm has a market cap of $2.13 billion and a PE ratio of -12.48.

Wall Street Analysts Forecast Growth

HTFL has been the topic of several recent analyst reports. JPMorgan Chase & Co. cut their price target on shares of Heartflow from $40.00 to $35.00 and set an “overweight” rating on the stock in a report on Thursday, March 19th. Wells Fargo & Company dropped their target price on shares of Heartflow from $38.00 to $35.00 and set an “overweight” rating for the company in a research report on Thursday, March 19th. Canaccord Genuity Group upped their target price on shares of Heartflow from $40.00 to $43.00 and gave the company a “buy” rating in a research note on Thursday, March 19th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Heartflow in a research note on Monday, December 29th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $37.67.

Hedge Funds Weigh In On Heartflow

Large investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP increased its stake in Heartflow by 20.8% during the fourth quarter. Wellington Management Group LLP now owns 5,894,070 shares of the company’s stock valued at $171,812,000 after purchasing an additional 1,014,006 shares during the last quarter. Baillie Gifford & Co. bought a new position in shares of Heartflow in the 3rd quarter worth about $101,182,000. Bamco Inc. NY lifted its position in shares of Heartflow by 86.2% in the 4th quarter. Bamco Inc. NY now owns 2,303,877 shares of the company’s stock worth $67,158,000 after buying an additional 1,066,371 shares during the last quarter. Schusterman Interests LLC acquired a new position in shares of Heartflow in the 3rd quarter valued at about $65,274,000. Finally, Capricorn Investment Group LLC bought a new stake in shares of Heartflow during the 4th quarter valued at about $48,178,000.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.